FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3165486166> ?p ?o ?g. }

• W3165486166 endingPage "2167" @default.
• W3165486166 startingPage "2158" @default.
• W3165486166 abstract "Abstract Objectives Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the COVID-19 pandemic. The majority of patients experience asymptomatic to mild self-limited disease, but some cases progress to respiratory and multi-organ failure. However, so far, no approved antiviral therapy has been available for treatment of COVID-19. Sofosbuvir/velpatasvir (SOF/VEL) is an approved anti-HCV drug that is capable of suppressing other families of positive-sense RNA viruses with conserved polymerase and may be effective against SARS-CoV-2. This study was conducted to evaluate the efficacy of the SOF/VEL combination in addition to the national standard of care versus the national standard of care alone (hydroxychloroquine and lopinavir/ritonavir as well as supportive care) in patients with moderate to severe COVID-19 infection. Methods This single-centre, randomized, open-labelled, prospective clinical trial was done in patients with moderate to severe COVID-19 admitted to Farabi Hospital in Kermanshah Province, Iran. Eligible patients were randomly assigned in a 1:1 ratio to the SOF/VEL arm (SOF/VEL plus the national standard of care) or the control arm (the national standard of care alone). The main outcome of the study was the mortality on Day 28 after randomization. Secondary outcomes were time from the start of medication to clinical improvement, hospital length of stay, need for mechanical ventilation, duration of mechanical ventilation and conversion of RT–PCR results from positive to negative from the time of randomization to discharge. Adverse events were evaluated in all patients who started their assigned treatment. Results Between 11 April and 8 June 2020, 80 patients were recruited and randomly assigned into the SOF/VEL (n = 40) and control (n = 40) arms. The primary outcome was not significantly different between the two arms (P = 1.00). Secondary outcomes, including time to clinical improvement, hospital length of stay, need for mechanical ventilation, duration of mechanical ventilation and RT–PCR conversion, were not significantly different between arms either (P &gt; 0.05). SOF/VEL treatment and the national standard of care were tolerated similarly. Conclusions Although treatment with SOF/VEL was safe, adding SOF/VEL to the standard of care did not improve the clinical status or reduce mortality in patients with moderate to severe COVID-19. However, larger randomized clinical trials including more parameters are needed for accurate estimation of the efficacy of SOF/VEL." @default.
• W3165486166 created "2021-06-07" @default.
• W3165486166 creator A5001340591 @default.
• W3165486166 creator A5008865917 @default.
• W3165486166 creator A5009547582 @default.
• W3165486166 creator A5010750112 @default.
• W3165486166 creator A5010935928 @default.
• W3165486166 creator A5024257845 @default.
• W3165486166 creator A5027124845 @default.
• W3165486166 creator A5028853982 @default.
• W3165486166 creator A5029589628 @default.
• W3165486166 creator A5037475331 @default.
• W3165486166 creator A5067166009 @default.
• W3165486166 creator A5067505459 @default.
• W3165486166 creator A5072764314 @default.
• W3165486166 creator A5088187923 @default.
• W3165486166 creator A5089667822 @default.
• W3165486166 date "2021-05-25" @default.
• W3165486166 modified "2023-10-01" @default.
• W3165486166 title "Efficacy and safety of sofosbuvir/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-centre, randomized controlled trial" @default.
• W3165486166 cites W2068062063 @default.
• W3165486166 cites W2115555188 @default.
• W3165486166 cites W2124517342 @default.
• W3165486166 cites W2552412210 @default.
• W3165486166 cites W2793598447 @default.
• W3165486166 cites W3007227604 @default.
• W3165486166 cites W3009885589 @default.
• W3165486166 cites W3010336234 @default.
• W3165486166 cites W3010880616 @default.
• W3165486166 cites W3014356995 @default.
• W3165486166 cites W3015429854 @default.
• W3165486166 cites W3015741518 @default.
• W3165486166 cites W3017468403 @default.
• W3165486166 cites W3020512604 @default.
• W3165486166 cites W3022872787 @default.
• W3165486166 cites W3024220416 @default.
• W3165486166 cites W3033802766 @default.
• W3165486166 cites W3039202106 @default.
• W3165486166 cites W3060275525 @default.
• W3165486166 cites W3067080207 @default.
• W3165486166 cites W3072079143 @default.
• W3165486166 cites W3100004995 @default.
• W3165486166 cites W4252172964 @default.
• W3165486166 doi "https://doi.org/10.1093/jac/dkab152" @default.
• W3165486166 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8194643" @default.
• W3165486166 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34037760" @default.
• W3165486166 hasPublicationYear "2021" @default.
• W3165486166 type Work @default.
• W3165486166 sameAs 3165486166 @default.
• W3165486166 citedByCount "16" @default.
• W3165486166 countsByYear W31654861662021 @default.
• W3165486166 countsByYear W31654861662022 @default.
• W3165486166 countsByYear W31654861662023 @default.
• W3165486166 crossrefType "journal-article" @default.
• W3165486166 hasAuthorship W3165486166A5001340591 @default.
• W3165486166 hasAuthorship W3165486166A5008865917 @default.
• W3165486166 hasAuthorship W3165486166A5009547582 @default.
• W3165486166 hasAuthorship W3165486166A5010750112 @default.
• W3165486166 hasAuthorship W3165486166A5010935928 @default.
• W3165486166 hasAuthorship W3165486166A5024257845 @default.
• W3165486166 hasAuthorship W3165486166A5027124845 @default.
• W3165486166 hasAuthorship W3165486166A5028853982 @default.
• W3165486166 hasAuthorship W3165486166A5029589628 @default.
• W3165486166 hasAuthorship W3165486166A5037475331 @default.
• W3165486166 hasAuthorship W3165486166A5067166009 @default.
• W3165486166 hasAuthorship W3165486166A5067505459 @default.
• W3165486166 hasAuthorship W3165486166A5072764314 @default.
• W3165486166 hasAuthorship W3165486166A5088187923 @default.
• W3165486166 hasAuthorship W3165486166A5089667822 @default.
• W3165486166 hasBestOaLocation W31654861661 @default.
• W3165486166 hasConcept C126322002 @default.
• W3165486166 hasConcept C142462285 @default.
• W3165486166 hasConcept C159047783 @default.
• W3165486166 hasConcept C168563851 @default.
• W3165486166 hasConcept C197934379 @default.
• W3165486166 hasConcept C2522874641 @default.
• W3165486166 hasConcept C2777080012 @default.
• W3165486166 hasConcept C2777182164 @default.
• W3165486166 hasConcept C2779134260 @default.
• W3165486166 hasConcept C2779298103 @default.
• W3165486166 hasConcept C2781392899 @default.
• W3165486166 hasConcept C2993143319 @default.
• W3165486166 hasConcept C3008058167 @default.
• W3165486166 hasConcept C524204448 @default.
• W3165486166 hasConcept C535046627 @default.
• W3165486166 hasConcept C71924100 @default.
• W3165486166 hasConceptScore W3165486166C126322002 @default.
• W3165486166 hasConceptScore W3165486166C142462285 @default.
• W3165486166 hasConceptScore W3165486166C159047783 @default.
• W3165486166 hasConceptScore W3165486166C168563851 @default.
• W3165486166 hasConceptScore W3165486166C197934379 @default.
• W3165486166 hasConceptScore W3165486166C2522874641 @default.
• W3165486166 hasConceptScore W3165486166C2777080012 @default.
• W3165486166 hasConceptScore W3165486166C2777182164 @default.
• W3165486166 hasConceptScore W3165486166C2779134260 @default.
• W3165486166 hasConceptScore W3165486166C2779298103 @default.
• W3165486166 hasConceptScore W3165486166C2781392899 @default.
• W3165486166 hasConceptScore W3165486166C2993143319 @default.

• next